Hematology. American Society of Hematology. Education Program

Keyphrases

Publications

volume 2023, number 1, 2024

Jeanne Palmer
Are transplant indications changing for myelofibrosis? Hematology. American Society of Hematology. Education Program 2023 (1) (2024)
Joanna M Rhodes, Carlos A Lopez, Jacqueline C Barrientos
MRD-directed therapy in CLL: ready for prime time? Hematology. American Society of Hematology. Education Program 2023 (1) (2024)
Rebecca Epperly, Nirali N Shah
Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. Hematology. American Society of Hematology. Education Program 2023 (1) (2024)
Beatrice Razzo, Alfred L Garfall, Adam D Cohen
Options at the time of relapse after anti-BCMA therapy. Hematology. American Society of Hematology. Education Program 2023 (1) (2024)
Timothy S Olson
Management of Fanconi anemia beyond childhood. Hematology. American Society of Hematology. Education Program 2023 (1) (2024)
Beatrice Razzo, Alfred L Garfall, Adam D Cohen
Options at the time of relapse after anti-BCMA therapy. Hematology. American Society of Hematology. Education Program 2023 (1) (2024)
Beatrice Razzo, Alfred L Garfall, Adam D Cohen
Options at the time of relapse after anti-BCMA therapy. Hematology. American Society of Hematology. Education Program 2023 (1) (2024)
Timothy S Olson
Management of Fanconi anemia beyond childhood. Hematology. American Society of Hematology. Education Program 2023 (1) (2024)
Simona Soverini
Resistance mutations in CML and how we approach them. Hematology. American Society of Hematology. Education Program 2023 (1) (2024)
Rebecca Epperly, Nirali N Shah
Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. Hematology. American Society of Hematology. Education Program 2023 (1) (2024)
Aimee C Talleur, Swati Naik, Stephen Gottschalk
Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells. Hematology. American Society of Hematology. Education Program 2023 (1) (2024)
Jeanne Palmer
Are transplant indications changing for myelofibrosis? Hematology. American Society of Hematology. Education Program 2023 (1) (2024)
Aimee C Talleur, Swati Naik, Stephen Gottschalk
Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells. Hematology. American Society of Hematology. Education Program 2023 (1) (2024)
Joanna M Rhodes, Carlos A Lopez, Jacqueline C Barrientos
MRD-directed therapy in CLL: ready for prime time? Hematology. American Society of Hematology. Education Program 2023 (1) (2024)
Simona Soverini
Resistance mutations in CML and how we approach them. Hematology. American Society of Hematology. Education Program 2023 (1) (2024)

volume 2023, number 1, 2023

Monique Hartley-Brown, Ateh Zinkeng
Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Marion Subklewe, Veit Bücklein, David Sallman, Naval Daver
Novel immunotherapies in the treatment of AML: is there hope? Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Ashish Kumar, Eily Cournoyer, Leonard Naymagon
Inflamed-HLH, MAS, or something else? Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Mindy Goldman
MSM and blood donation: shifting to individualized risk assessment. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Ruemu Ejedafeta Birhiray, Maya Nicole Birhiray
Clinical research in the community. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
John C Molina, Seth Rotz
Leveraging health care technology to improve health outcomes and reduce outcome disparities in AYA leukemia. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Sangeetha Venugopal, Justin Watts
The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Harinder Gill, Garret M K Leung, Yok-Lam Kwong
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Cheryl Mensah, Sujit Sheth
When should gene therapy be considered for transfusion-dependent β-thalassemia patients? Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Michael H Kroll
Checkpoint inhibitors. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Naranie Shanmuganathan, Timothy P Hughes
Accelerated-phase CML: de novo and transformed. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Amber Afzal, Jordan Schaefer
Direct oral anticoagulants to treat deep venous thrombosis and pulmonary embolism in patients with cirrhosis: are we there yet? Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Rohith Jesudas, Clifford M Takemoto
Where have all the platelets gone? HIT, DIC, or something else? Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Onyee Chan, Alison R Walker
Novel therapies upon failure of HMA plus venetoclax. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Adi Zoref-Lorenz, Martin Ellis, Michael B Jordan
Inpatient recognition and management of HLH. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
France Pirenne, Corinne Pondarré
Alloimmunization and hyperhemolysis in sickle cell disease. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Kai Rejeski, Marion Subklewe, Frederick L Locke
Recognizing, defining, and managing CAR-T hematologic toxicities. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Sanyukta K Janardan, Tamara P Miller
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Jacqueline Poston, Rebecca Kruse-Jarres
The role of emicizumab in acquired hemophilia A. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Beatrice Razzo, Alfred L Garfall, Adam D Cohen
Options at the time of relapse after anti-BCMA therapy. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Barry Kevane, Fionnuala Ní Áinle
Prevention, diagnosis, and management of PE and DVT in pregnant women. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Marie Sébert
Next-generation therapy for lower-risk MDS. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Douglas Tremblay
Cytoreduction for ET and PV: who, what, when, and how? Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Andreas Tiede
Immunotherapy of acquired hemophilia A. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Andra H James, Luis D Pacheco, Barbara A Konkle
Management of pregnant women who have bleeding disorders. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Zahra Hudda, Kasiani C Myers
Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes? Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Scott Veitch, Deepti H Radia
Mastocytosis demystified. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
David A Sallman, Zhuoer Xie
Frontline treatment options for higher-risk MDS: can we move past azacitidine? Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Heather J Male, Tara L Lin
The approach of HMA plus VEN with or without BMT for all patients with AML. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Benjamin Watkins, Muna Qayed
Novel approaches to acute graft-versus-host disease prevention. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Ton Lisman
How to assess hemostasis in patients with severe liver disease. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Jacob Rozmus, John E Levine, Kirk R Schultz
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Timothy S Olson
Management of Fanconi anemia beyond childhood. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Anoosha Habibi, Alexandra Benachi, Edouard Lecarpentier
Managing pregnancy in patients with sickle cell disease from a transfusion perspective. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)
Chijioke Nze, Christopher R Flowers
Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology. American Society of Hematology. Education Program 2023 (1) (2023)